2019
DOI: 10.1186/s13054-019-2369-x
|View full text |Cite
|
Sign up to set email alerts
|

Resuscitation Fluid Choices to Preserve the Endothelial Glycocalyx

Abstract: This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2019. Other selected articles can be found online at https://www.biomedcentral.com/collections/annualupdate2019 . Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901 .

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
73
0
2

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 98 publications
(76 citation statements)
references
References 53 publications
1
73
0
2
Order By: Relevance
“…Preservation of this layer by preventing shedding of glycocalyx components, or accelerating repair may be a potential therapeutic target (20). Although no therapeutic agents to abrogate glycocalyx breakdown have yet been investigated in humans with dengue, interest is growing in the potential to translate therapeutics developed for other indications; these include strategies to inhibit heparanase activity [modified heparins, Sulodexide (24)], downregulate MMP activity to reduce proteoglycan shedding [S1P analogs (25,26)], use intravenous fluids (IV) which may accelerate glycocalyx repair (27) [albumin (28), fresh frozen plasma (29)], or avoid bolus administration of IV fluids to prevent further damage to a fragile glycocalyx (30). However, screening of such therapeutic strategies for vascular leak in dengue requires an improvement in vitro models to evaluate glycocalyx integrity.…”
Section: Discussionmentioning
confidence: 99%
“…Preservation of this layer by preventing shedding of glycocalyx components, or accelerating repair may be a potential therapeutic target (20). Although no therapeutic agents to abrogate glycocalyx breakdown have yet been investigated in humans with dengue, interest is growing in the potential to translate therapeutics developed for other indications; these include strategies to inhibit heparanase activity [modified heparins, Sulodexide (24)], downregulate MMP activity to reduce proteoglycan shedding [S1P analogs (25,26)], use intravenous fluids (IV) which may accelerate glycocalyx repair (27) [albumin (28), fresh frozen plasma (29)], or avoid bolus administration of IV fluids to prevent further damage to a fragile glycocalyx (30). However, screening of such therapeutic strategies for vascular leak in dengue requires an improvement in vitro models to evaluate glycocalyx integrity.…”
Section: Discussionmentioning
confidence: 99%
“…Starling originally hypothesized in 1896 that opposing hydrostatic and oncotic pressures in the capillaries of the microcirculation determined fluid flow between the intravascular and interstitial fluid compartments (28). In line with this model administration of colloids became an accepted strategy for management of hypovolaemic shock (37)]. EGL, endothelial glycocalyx layer.…”
Section: Dengue Associated Vascular Leakage In the Context Of The Revmentioning
confidence: 99%
“…fluid reabsorption as dictated by the original Starling model (31,(35)(36)(37). Any fluid that is filtered returns to the circulation via lymphatic channels; in response to increased pressure in local lymphatics, fluid flow toward the thoracic duct increases markedly, but the protein (primarily albumin) content of the returned fluid is low compared to plasma (31).…”
Section: Dengue Associated Vascular Leakage In the Context Of The Revmentioning
confidence: 99%
See 1 more Smart Citation
“…The high molecular weight of the dissolved colloid molecules contributes to oncotic pressure to retain water within the intravascular space (Pachtinger & Drobatz 2008). Colloids may be considered advantageous in the treatment of recurrent hypovolaemia and/or hypoproteinemia, particularly if the glycocalyx integrity is still preserved (Milford & Reade 2019). Colloids can be divided into natural products, such as plasma or albumin, and synthetic products including gelatins, hydroxyethyl starches (HES) and dextrans.…”
Section: Introductionmentioning
confidence: 99%